PharmGen Science（A004720）株式概要韓国で医薬品の研究開発、製造、販売を行っている。 詳細A004720 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績1/6財務の健全性4/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 財務結果に影響を与える大きな一時的項目 利益率(0.07%)は昨年より低い(3.8%) 過去1年間で株主の希薄化が進んだ +1 さらなるリスクすべてのリスクチェックを見るA004720 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW485,374 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA485,374 investors already sharing narrativesYour Fair Value₩Current Price₩3.33k40.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1b172b2016201920222025202620282031Revenue ₩171.7bEarnings ₩117.8mAdvancedSet Fair ValueView all narrativesPharmGen Science, Inc. 競合他社Sam-A PharmSymbol: KOSDAQ:A009300Market cap: ₩75.7bTheragen EtexLtdSymbol: KOSDAQ:A066700Market cap: ₩80.7bEnzychem LifesciencesSymbol: KOSDAQ:A183490Market cap: ₩76.4bDK Life ScienceSymbol: KOSDAQ:A303810Market cap: ₩77.9b価格と性能株価の高値、安値、推移の概要PharmGen Science過去の株価現在の株価₩3,325.0052週高値₩4,645.0052週安値₩2,590.00ベータ0.221ヶ月の変化4.23%3ヶ月変化-16.88%1年変化-26.92%3年間の変化-42.77%5年間の変化-71.46%IPOからの変化-71.09%最新ニュースNew Risk • May 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩81.6b market cap, or US$54.4m).お知らせ • Mar 14PharmGen Science, Inc., Annual General Meeting, Mar 31, 2026PharmGen Science, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 50, jeyakgongdan 2-gil, hyangnam-eup, gyeonggi-do, hwaseong South KoreaNew Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩96.4b market cap, or US$66.8m).New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Market cap is less than US$100m (₩75.8b market cap, or US$51.5m).分析記事 • Mar 30Some Investors May Be Willing To Look Past PharmGen Science's (KRX:004720) Soft EarningsShareholders appeared unconcerned with PharmGen Science, Inc.'s ( KRX:004720 ) lackluster earnings report last week. We...New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 2.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.4% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩72.6b market cap, or US$49.4m).最新情報をもっと見るRecent updatesNew Risk • May 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩81.6b market cap, or US$54.4m).お知らせ • Mar 14PharmGen Science, Inc., Annual General Meeting, Mar 31, 2026PharmGen Science, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 50, jeyakgongdan 2-gil, hyangnam-eup, gyeonggi-do, hwaseong South KoreaNew Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩96.4b market cap, or US$66.8m).New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Market cap is less than US$100m (₩75.8b market cap, or US$51.5m).分析記事 • Mar 30Some Investors May Be Willing To Look Past PharmGen Science's (KRX:004720) Soft EarningsShareholders appeared unconcerned with PharmGen Science, Inc.'s ( KRX:004720 ) lackluster earnings report last week. We...New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 2.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.4% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩72.6b market cap, or US$49.4m).お知らせ • Mar 13PharmGen Science, Inc., Annual General Meeting, Mar 31, 2025PharmGen Science, Inc., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 50, jeyakgongdan 2-gil, hyangnam-eup, gyeonggi-do, hwaseong South Korea分析記事 • Aug 12PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some RiskWhen close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 11x, you may consider...分析記事 • Mar 27PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft EarningsThe subdued market reaction suggests that PharmGen Science, Inc.'s ( KRX:004720 ) recent earnings didn't contain any...Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩352 (vs ₩4,498 in FY 2022)Full year 2023 results: EPS: ₩352 (down from ₩4,498 in FY 2022). Revenue: ₩166.8b (up 11% from FY 2022). Net income: ₩5.73b (down 92% from FY 2022). Profit margin: 3.4% (down from 46% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.New Risk • Oct 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (5.0% net profit margin). Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩98.4b market cap, or US$72.9m).Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,560, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 58% over the past three years.Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩4,498 (vs ₩2,206 in FY 2021)Full year 2022 results: EPS: ₩4,498 (up from ₩2,206 in FY 2021). Revenue: ₩150.9b (up 37% from FY 2021). Net income: ₩70.1b (up 116% from FY 2021). Profit margin: 46% (up from 30% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,400, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩12,600, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 88% over the past three years.Valuation Update With 7 Day Price Move • Sep 23Investor sentiment improved over the past weekAfter last week's 40% share price gain to ₩13,650, the stock trades at a trailing P/E ratio of 8.3x. Average trailing P/E is 28x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 52% over the past three years.Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩9,820, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 19% over the past three years.Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩14,250, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 61% over the past three years.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩12,350, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 42% over the past three years.お知らせ • Jun 12PharmGen Science Inc. announced that it has received KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) LimitedOn June 11, 2021, PharmGen Science Inc. (KOSE:A004720) closed the transaction.Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₩10,400, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 3.7% over the past three years.お知らせ • May 18PharmGen Science Inc. announced that it expects to receive KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) LimitedPharmGen Science Inc. (KOSE:A004720) announced a private placement of series 33 unregistered coupon non-guaranteed secured private convertible bond at an issue price of KRW 30,000,000,000 for gross proceeds of KRW 30,000,000,000 on May 17, 2021. The transaction will include participation from returning investors SC Lowy Financial (HK) Limited and Linden Capital L.P., a fund managed by Linden Advisors LP for KRW 15,000,000,000 each. The surface interest rate of the bonds is 3.5% and interest rate to maturity is 3.5%. The bonds will mature on May 27, 2026. The bonds will be convertible into 2,255,639 shares at conversion price of KRW 13,300. The conversion period of the bonds will start from May 27, 2022 and end on April 27, 2026. The subscription date of the transaction is May 20, 2021 and payment date is May 27, 2021. The transaction has been approved by the board of directors of the company. The securities are subject to hold period of one year.Valuation Update With 7 Day Price Move • May 01Investor sentiment improved over the past weekAfter last week's 42% share price gain to ₩15,750, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 41% over the past three years.Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improved over the past weekAfter last week's 26% share price gain to ₩11,450, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 29x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 16% over the past three years.分析記事 • Mar 21Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Mar 21Full year 2020 earnings released: EPS ₩675 (vs ₩26.00 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩96.6b (up 1.6% from FY 2019). Net income: ₩9.22b (up ₩8.92b from FY 2019). Profit margin: 9.5% (up from 0.3% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Mar 05Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Feb 23New 90-day low: ₩9,180The company is down 23% from its price of ₩12,000 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: ₩9,340The company is down 27% from its price of ₩12,750 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.分析記事 • Jan 19Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%While Wooridul Pharmaceutical Limited ( KRX:004720 ) shareholders are probably generally happy, the stock hasn't had...Is New 90 Day High Low • Jan 11New 90-day low: ₩10,350The company is down 38% from its price of ₩16,800 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩10,800, the stock is trading at a trailing P/E ratio of 63.2x, down from the previous P/E ratio of 75.2x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total return to shareholders over the past three years is a loss of 5.7%.Is New 90 Day High Low • Dec 24New 90-day low: ₩11,800The company is down 20% from its price of ₩14,800 on 25 September 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 17% over the same period.分析記事 • Dec 21Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?It is hard to get excited after looking at Wooridul Pharmaceutical's (KRX:004720) recent performance, when its stock...Is New 90 Day High Low • Dec 04New 90-day low: ₩11,900The company is down 38% from its price of ₩19,150 on 04 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.分析記事 • Nov 25Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?As a general rule, we think profitable companies are less risky than companies that lose money. However, sometimes...Is New 90 Day High Low • Nov 17New 90-day low: ₩12,250The company is down 40% from its price of ₩20,300 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.お知らせ • Nov 12Wooridul Pharmaceutical Limited announced that it expects to receive KRW 20 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) LimitedWooridul Pharmaceutical Limited (KOSE:A004720) announced a private placement of 32 series unregistered coupon non-guaranteed private bonds with warrants for gross proceeds of KRW 20,000,000,000 on November 11, 2020. The company will also issue warrants exercisable into 1,342,281 shares with an exercise price of KRW 14,900 for 9.12% stake in the company during November 19, 2021 and October 19, 2023. The bond is issued at 2.5% coupon rate, 2.5% yield to maturity rate and will mature on November 19, 2023. The transaction will include participation from new investor Linden Capital L.P , a fund managed by Linden Advisors LP and SC Lowy Financial (HK) Limited for KRW 10,000,000,000 each. The subscription date is November 13, 2020 and the payment date is November 19, 2020. The securities are subjected to hold period of 1 year. The transaction has been approved by the board of directors of the company.株主還元A004720KR PharmaceuticalsKR 市場7D1.5%-2.4%-7.1%1Y-26.9%-14.2%87.9%株主還元を見る業界別リターン: A004720過去 1 年間で-14.2 % の収益を上げたKR Pharmaceuticals業界を下回りました。リターン対市場: A004720は、過去 1 年間で87.9 % のリターンを上げたKR市場を下回りました。価格変動Is A004720's price volatile compared to industry and market?A004720 volatilityA004720 Average Weekly Movement6.8%Pharmaceuticals Industry Average Movement7.1%Market Average Movement9.8%10% most volatile stocks in KR Market17.7%10% least volatile stocks in KR Market5.1%安定した株価: A004720 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A004720の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1966226Hee-Deok Parkwww.wooridulpharm.com韓国で医薬品の研究開発、製造、販売を行っている。医療用医薬品、一般用医薬品、診断用検査キット、健康食品、一般食品、化粧品、ネオムセルのブランド名でシャンプー、コンディショナー、ヘアオイル製品を提供している。以前はウーリドゥル・ファーマシューティカル・リミテッドとして知られていたが、ファームジェン・サイエンス社に社名変更した。ファームジェン・サイエンス社は1957年に設立され、本社は韓国華城市にある。もっと見るPharmGen Science, Inc. 基礎のまとめPharmGen Science の収益と売上を時価総額と比較するとどうか。A004720 基礎統計学時価総額₩75.19b収益（TTM）₩117.75m売上高(TTM)₩171.66b638.5xPER（株価収益率0.4xP/SレシオA004720 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A004720 損益計算書（TTM）収益₩171.66b売上原価₩63.30b売上総利益₩108.36bその他の費用₩108.24b収益₩117.75m直近の収益報告Mar 31, 2025次回決算日該当なし一株当たり利益（EPS）5.21グロス・マージン63.12%純利益率0.069%有利子負債／自己資本比率7.6%A004720 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/04 22:30終値2026/08/04 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PharmGen Science, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩81.6b market cap, or US$54.4m).
お知らせ • Mar 14PharmGen Science, Inc., Annual General Meeting, Mar 31, 2026PharmGen Science, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 50, jeyakgongdan 2-gil, hyangnam-eup, gyeonggi-do, hwaseong South Korea
New Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩96.4b market cap, or US$66.8m).
New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Market cap is less than US$100m (₩75.8b market cap, or US$51.5m).
分析記事 • Mar 30Some Investors May Be Willing To Look Past PharmGen Science's (KRX:004720) Soft EarningsShareholders appeared unconcerned with PharmGen Science, Inc.'s ( KRX:004720 ) lackluster earnings report last week. We...
New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 2.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.4% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩72.6b market cap, or US$49.4m).
New Risk • May 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩81.6b market cap, or US$54.4m).
お知らせ • Mar 14PharmGen Science, Inc., Annual General Meeting, Mar 31, 2026PharmGen Science, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 50, jeyakgongdan 2-gil, hyangnam-eup, gyeonggi-do, hwaseong South Korea
New Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩96.4b market cap, or US$66.8m).
New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.07% net profit margin). Market cap is less than US$100m (₩75.8b market cap, or US$51.5m).
分析記事 • Mar 30Some Investors May Be Willing To Look Past PharmGen Science's (KRX:004720) Soft EarningsShareholders appeared unconcerned with PharmGen Science, Inc.'s ( KRX:004720 ) lackluster earnings report last week. We...
New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 2.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.4% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩72.6b market cap, or US$49.4m).
お知らせ • Mar 13PharmGen Science, Inc., Annual General Meeting, Mar 31, 2025PharmGen Science, Inc., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 50, jeyakgongdan 2-gil, hyangnam-eup, gyeonggi-do, hwaseong South Korea
分析記事 • Aug 12PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some RiskWhen close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 11x, you may consider...
分析記事 • Mar 27PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft EarningsThe subdued market reaction suggests that PharmGen Science, Inc.'s ( KRX:004720 ) recent earnings didn't contain any...
Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩352 (vs ₩4,498 in FY 2022)Full year 2023 results: EPS: ₩352 (down from ₩4,498 in FY 2022). Revenue: ₩166.8b (up 11% from FY 2022). Net income: ₩5.73b (down 92% from FY 2022). Profit margin: 3.4% (down from 46% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.
New Risk • Oct 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (5.0% net profit margin). Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩98.4b market cap, or US$72.9m).
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,560, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 58% over the past three years.
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩4,498 (vs ₩2,206 in FY 2021)Full year 2022 results: EPS: ₩4,498 (up from ₩2,206 in FY 2021). Revenue: ₩150.9b (up 37% from FY 2021). Net income: ₩70.1b (up 116% from FY 2021). Profit margin: 46% (up from 30% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,400, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩12,600, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 88% over the past three years.
Valuation Update With 7 Day Price Move • Sep 23Investor sentiment improved over the past weekAfter last week's 40% share price gain to ₩13,650, the stock trades at a trailing P/E ratio of 8.3x. Average trailing P/E is 28x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 52% over the past three years.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩9,820, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 19% over the past three years.
Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩14,250, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 61% over the past three years.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩12,350, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 42% over the past three years.
お知らせ • Jun 12PharmGen Science Inc. announced that it has received KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) LimitedOn June 11, 2021, PharmGen Science Inc. (KOSE:A004720) closed the transaction.
Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₩10,400, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 3.7% over the past three years.
お知らせ • May 18PharmGen Science Inc. announced that it expects to receive KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) LimitedPharmGen Science Inc. (KOSE:A004720) announced a private placement of series 33 unregistered coupon non-guaranteed secured private convertible bond at an issue price of KRW 30,000,000,000 for gross proceeds of KRW 30,000,000,000 on May 17, 2021. The transaction will include participation from returning investors SC Lowy Financial (HK) Limited and Linden Capital L.P., a fund managed by Linden Advisors LP for KRW 15,000,000,000 each. The surface interest rate of the bonds is 3.5% and interest rate to maturity is 3.5%. The bonds will mature on May 27, 2026. The bonds will be convertible into 2,255,639 shares at conversion price of KRW 13,300. The conversion period of the bonds will start from May 27, 2022 and end on April 27, 2026. The subscription date of the transaction is May 20, 2021 and payment date is May 27, 2021. The transaction has been approved by the board of directors of the company. The securities are subject to hold period of one year.
Valuation Update With 7 Day Price Move • May 01Investor sentiment improved over the past weekAfter last week's 42% share price gain to ₩15,750, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 41% over the past three years.
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improved over the past weekAfter last week's 26% share price gain to ₩11,450, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 29x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 16% over the past three years.
分析記事 • Mar 21Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Mar 21Full year 2020 earnings released: EPS ₩675 (vs ₩26.00 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩96.6b (up 1.6% from FY 2019). Net income: ₩9.22b (up ₩8.92b from FY 2019). Profit margin: 9.5% (up from 0.3% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 05Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Feb 23New 90-day low: ₩9,180The company is down 23% from its price of ₩12,000 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: ₩9,340The company is down 27% from its price of ₩12,750 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
分析記事 • Jan 19Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%While Wooridul Pharmaceutical Limited ( KRX:004720 ) shareholders are probably generally happy, the stock hasn't had...
Is New 90 Day High Low • Jan 11New 90-day low: ₩10,350The company is down 38% from its price of ₩16,800 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩10,800, the stock is trading at a trailing P/E ratio of 63.2x, down from the previous P/E ratio of 75.2x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total return to shareholders over the past three years is a loss of 5.7%.
Is New 90 Day High Low • Dec 24New 90-day low: ₩11,800The company is down 20% from its price of ₩14,800 on 25 September 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 17% over the same period.
分析記事 • Dec 21Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?It is hard to get excited after looking at Wooridul Pharmaceutical's (KRX:004720) recent performance, when its stock...
Is New 90 Day High Low • Dec 04New 90-day low: ₩11,900The company is down 38% from its price of ₩19,150 on 04 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
分析記事 • Nov 25Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?As a general rule, we think profitable companies are less risky than companies that lose money. However, sometimes...
Is New 90 Day High Low • Nov 17New 90-day low: ₩12,250The company is down 40% from its price of ₩20,300 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
お知らせ • Nov 12Wooridul Pharmaceutical Limited announced that it expects to receive KRW 20 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) LimitedWooridul Pharmaceutical Limited (KOSE:A004720) announced a private placement of 32 series unregistered coupon non-guaranteed private bonds with warrants for gross proceeds of KRW 20,000,000,000 on November 11, 2020. The company will also issue warrants exercisable into 1,342,281 shares with an exercise price of KRW 14,900 for 9.12% stake in the company during November 19, 2021 and October 19, 2023. The bond is issued at 2.5% coupon rate, 2.5% yield to maturity rate and will mature on November 19, 2023. The transaction will include participation from new investor Linden Capital L.P , a fund managed by Linden Advisors LP and SC Lowy Financial (HK) Limited for KRW 10,000,000,000 each. The subscription date is November 13, 2020 and the payment date is November 19, 2020. The securities are subjected to hold period of 1 year. The transaction has been approved by the board of directors of the company.
